Payment overview · 2025
General Payments
$1,070.27
45 reported records · 15 companies
Healthcare provider profile · identity verified
Anthony Joseph Rizzo, DO
Allopathic & Osteopathic Physicians|Family Medicine · BAY SHORE, NY · NPI 1194736470
Verified facts
What the public records show
CMS Open Payments records show Anthony Joseph Rizzo, DO received $1,070.27 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $261.74 | 24.5% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $164.02 | 15.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $120.52 | 11.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.74 | 9.4% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.57 | 8.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.33 | 5.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $47.87 | 4.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.82 | 4.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.38 | 4.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.54 | 2.6% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $27.31 | 2.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.42 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.01 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.74 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.26 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $985.28 | 44 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $224.38 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $203.87 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $166.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $140.39 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $120.52 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $79.03 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.33 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.33 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.16 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $47.87 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $45.38 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $45.38 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $27.54 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $27.31 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1461 | 490 |
| Levothyroxine Sodium | Levothyroxine Sodium | 863 | 284 |
| Amlodipine Besylate | Amlodipine Besylate | 814 | 283 |
| Metoprolol Succinate | Metoprolol Succinate | 749 | 275 |
| Losartan Potassium | Losartan Potassium | 661 | 228 |
| Eliquis | Apixaban | 602 | 145 |
| Metformin Hcl | Metformin Hcl | 543 | 184 |
| Gabapentin | Gabapentin | 536 | 182 |
| Pantoprazole Sodium | Pantoprazole Sodium | 526 | 227 |
| Simvastatin | Simvastatin | 516 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 153 |
| Metoprolol Tartrate | Metoprolol Tartrate | 424 | 137 |
| Tamsulosin Hcl | Tamsulosin Hcl | 424 | 157 |
| Hydrochlorothiazide | Hydrochlorothiazide | 423 | 159 |
| Sertraline Hcl | Sertraline Hcl | 406 | 108 |
| Alprazolam | Alprazolam | 403 | 127 |
| Furosemide | Furosemide | 383 | 152 |
| Escitalopram Oxalate | Escitalopram Oxalate | 382 | 123 |
| Lisinopril | Lisinopril | 370 | 118 |
| Trazodone Hcl | Trazodone Hcl | 359 | 112 |
| Omeprazole | Omeprazole | 353 | 120 |
| Mirtazapine | Mirtazapine | 325 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 313 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 289 | 94 |
| Famotidine | Famotidine | 284 | 98 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 63 |
| Potassium Chloride | Potassium Chloride | 245 | 84 |
| Meloxicam | Meloxicam | 227 | 96 |
| Memantine Hcl | Memantine Hcl | 222 | 49 |
| Donepezil Hcl | Donepezil Hcl | 221 | 73 |
| Montelukast Sodium | Montelukast Sodium | 221 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 214 | 53 |
| Allopurinol | Allopurinol | 211 | 69 |
| Carvedilol | Carvedilol | 204 | 74 |
| Oxycodone Hcl | Oxycodone Hcl | 198 | 61 |
| Hydralazine Hcl | Hydralazine Hcl | 195 | 66 |
| Ezetimibe | Ezetimibe | 183 | 69 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 172 | 54 |
| Tramadol Hcl | Tramadol Hcl | 167 | 64 |
| Azithromycin | Azithromycin | 162 | 118 |
| Spironolactone | Spironolactone | 142 | 69 |
| Xarelto | Rivaroxaban | 142 | 36 |
| Divalproex Sodium | Divalproex Sodium | 141 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 62 |
| Ibuprofen | Ibuprofen | 135 | 49 |
| Metformin Hcl Er | Metformin Hcl | 133 | 44 |
| Januvia | Sitagliptin Phosphate | 131 | 33 |
| Ozempic | Semaglutide | 131 | 42 |
| Prednisone | Prednisone | 128 | 69 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 35 |
| Atenolol | Atenolol | 122 | 43 |
| Valsartan | Valsartan | 119 | 35 |
| Baclofen | Baclofen | 118 | 39 |
| Ketoconazole | Ketoconazole | 118 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 33 |
| Finasteride | Finasteride | 112 | 42 |
| Ipratropium Bromide | Ipratropium Bromide | 112 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 41 |
| Levetiracetam | Levetiracetam | 108 | 31 |
| Warfarin Sodium | Warfarin Sodium | 104 | 24 |
| Buspirone Hcl | Buspirone Hcl | 102 | 25 |
| Enalapril Maleate | Enalapril Maleate | 102 | 33 |
| Methocarbamol | Methocarbamol | 102 | 50 |
| Bupropion Xl | Bupropion Hcl | 101 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 101 | 75 |
| Alendronate Sodium | Alendronate Sodium | 100 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 33 |
| Lorazepam | Lorazepam | 99 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 33 |
| Synthroid | Levothyroxine Sodium | 98 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 39 |
| Farxiga | Dapagliflozin Propanediol | 96 | 33 |
| Torsemide | Torsemide | 95 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 94 | 82 |
| Clonazepam | Clonazepam | 94 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 92 | 78 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 66 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 86 | 29 |
| Ramipril | Ramipril | 84 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 30 |
| Diazepam | Diazepam | 77 | 31 |
| Glimepiride | Glimepiride | 77 | 28 |
| Celecoxib | Celecoxib | 76 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 75 | 41 |
| Sucralfate | Sucralfate | 75 | 27 |
| Midodrine Hcl | Midodrine Hcl | 73 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 48 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 72 | 27 |
| Trulicity | Dulaglutide | 72 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 72 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 24 |
| Glipizide Er | Glipizide | 67 | 22 |
| Latanoprost | Latanoprost | 67 | 31 |
| Dexamethasone | Dexamethasone | 66 | 45 |
| Jardiance | Empagliflozin | 65 | 21 |
| Vascepa | Icosapent Ethyl | 65 | 22 |
| Olanzapine | Olanzapine | 59 | 22 |
| Bumetanide | Bumetanide | 57 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 46 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 20 |
| Retacrit | Epoetin Alfa-Epbx | 54 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 29 |
| Acyclovir | Acyclovir | 51 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 51 | 13 |
| Meclizine Hcl | Meclizine Hcl | 51 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 13 |
| Pregabalin | Pregabalin | 50 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 23 |
| Nifedipine Er | Nifedipine | 48 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 47 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | 19 |
| Linzess | Linaclotide | 46 | 22 |
| Cephalexin | Cephalexin | 45 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 15 |
| Nystatin | Nystatin | 45 | 29 |
| Lovastatin | Lovastatin | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 14 |
| Azelastine Hcl | Azelastine Hcl | 41 | 21 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Risperidone | Risperidone | 41 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 22 |
| Clonidine Hcl | Clonidine Hcl | 40 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 20 |
| Digoxin | Digoxin | 40 | 16 |
| Lansoprazole | Lansoprazole | 40 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 12 |
| Gemtesa | Vibegron | 39 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 19 |
| Primidone | Primidone | 39 | 15 |
| Silver Sulfadiazine | Silver Sulfadiazine | 39 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 38 | 24 |
| Methenamine Hippurate | Methenamine Hippurate | 38 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 20 |
| Daptomycin | Daptomycin | 36 | suppressed |
| Glipizide | Glipizide | 34 | 15 |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 34 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | 14 |
| Entresto | Sacubitril/Valsartan | 33 | 21 |
| Hydrocortisone | Hydrocortisone | 33 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | 12 |
| Xtampza Er | Oxycodone Myristate | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | 15 |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 15 |
| Tiadylt Er | Diltiazem Hcl | 30 | 14 |
| Nyamyc | Nystatin | 29 | 16 |
| Scopolamine | Scopolamine | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 26 | 19 |
| Levofloxacin | Levofloxacin | 26 | 25 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 14 |
| Mupirocin | Mupirocin | 26 | 18 |
| Naproxen | Naproxen | 26 | 14 |
| Ssd | Silver Sulfadiazine | 26 | 17 |
| Brilinta | Ticagrelor | 25 | 11 |
| Metronidazole | Metronidazole | 25 | 16 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 24 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | 11 |
| Methimazole | Methimazole | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | 15 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 20 | suppressed |
| Letrozole | Letrozole | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 20 | 18 |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | 13 |
| Ammonium Lactate | Ammonium Lactate | 19 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 16 |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 13 |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Octreotide Acetate | Octreotide Acetate | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 15 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Phenytoin | Phenytoin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,070.27 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DUPIXENT, Dexcom G6 Transmitter, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, IBSRELA, INSPIRE, LEQVIO, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VERQUVO, VRAYLAR, Veozah | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error